Analgesic Effects of Low-dose S-ketamine in Major Spine Fusion Surgery
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Despite opioid-based multimodal analgesia, moderate-to-severe pain remains a big problem in
patients following multi-segment spinal fusion. As a N-methyl-D-aspartate receptor
antagonist, S-ketamine has prominent analgesic effects through activating receptors both in
the brain and in the spinal cord, inhibiting the excitatory postsynaptic potential, and thus
blunting nociception transmission.
This randomized controlled trial is designed to investigate whether perioperative S-ketamine
infusion can decrease pain intensity after major spine fusion surgery.